Australian Broker Call

Produced and copyrighted by at www.fnarena.com

November 23, 2020

Access Broker Call Report Archives here

COMPANIES DISCUSSED IN THIS ISSUE

Click on symbol for fast access.

The number next to the symbol represents the number of brokers covering it for this report -(if more than 1).

Last Updated: 05:00 PM

Your daily news report on the latest recommendation, valuation, forecast and opinion changes.

This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.

For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE

Today's Upgrades and Downgrades
ALX - Atlas Arteria Downgrade to Neutral from Outperform Macquarie
AX1 - Accent Group Upgrade to Buy from Neutral Citi
CCX - City Chic Upgrade to Buy from Neutral Citi
IAG - Insurance Australia Downgrade to Neutral from Buy Citi
ORI - Orica Upgrade to Add from Hold Morgans
OSH - Oil Search Downgrade to Hold from Add Morgans
VRT - Virtus Health Downgrade to Hold from Add Morgans
3PL  3P LEARNING LIMITED

Education & Tuition

More Research Tools In Stock Analysis - click HERE

Overnight Price: $1.38

Morgan Stanley rates 3PL as Overweight (1) -

The IXL scheme of arrangement was voted down.

Subsequently, 25% shareholder Viburnum put forward a proposal whereby 3P Learning would acquire its longtime product partner Blake eLearning for $188m. If successful the transaction is due to complete March 22, 2021.

The transaction would result in 3P Learning shareholders owning 53% of a group with an implied valuation of around $360m.

Viburnum estimates pro forma FY21 revenue of $114m and pro forma earnings (EBIT) of $38m before cost synergies of $10m.

The broker maintains its Overweight rating with a target price of $1.50. Industry view: In-line.

Target price is $1.50 Current Price is $1.38 Difference: $0.12
If 3PL meets the Morgan Stanley target it will return approximately 9% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 0.00 cents and EPS of 9.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.33.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 EPS of 6.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 23.00.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ALX  ATLAS ARTERIA

Infrastructure & Utilities

More Research Tools In Stock Analysis - click HERE

Overnight Price: $6.73

Macquarie rates ALX as Downgrade to Neutral from Outperform (3) -

Atlas Arteria has surprised with a traffic update outside the quarter. Traffic has collapsed as expected due to the re-lockdown in France, but not as fas as Macquarie expected. Truck traffic remained largely unaffected.

The numbers are positive for dividend expectations but do not change the broker's earnings forecast of a strong rebound out of the virus impact. As this is captured in the share price, Macquarie downgrades to Neutral from Outperform.

Target falls to $6.68 from $6.73 on currency adjustments.

Target price is $6.68 Current Price is $6.73 Difference: minus $0.05 (current price is over target).
If ALX meets the Macquarie target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $6.87, suggesting upside of 4.2% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY20:

Macquarie forecasts a full year FY20 dividend of 11.00 cents and EPS of 51.00 cents.
At the last closing share price the estimated dividend yield is 1.63%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.20.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 14.6, implying annual growth of 484.0%.

Current consensus DPS estimate is 13.6, implying a prospective dividend yield of 2.1%.

Current consensus EPS estimate suggests the PER is 45.1.

Forecast for FY21:

Macquarie forecasts a full year FY21 dividend of 35.00 cents and EPS of 79.20 cents.
At the last closing share price the estimated dividend yield is 5.20%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 8.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 36.9, implying annual growth of 152.7%.

Current consensus DPS estimate is 31.6, implying a prospective dividend yield of 4.8%.

Current consensus EPS estimate suggests the PER is 17.9.

Market Sentiment: 0.2

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


UBS rates ALX as Neutral (3) -

In the first two weeks since France entered nationwide lockdown, traffic has been down to around half of what it was during late March and April.

Heavy vehicle traffic has held up and, hence, UBS estimates heavy vehicles are down around -5% and light vehicles down around -50%.

A slow recovery has continued in Virginia although the growing number of coronavirus cases and restrictions regarding mass gatherings makes UBS suspect it will be protracted.

Forecasts assume Dulles Greenway traffic declines -20% in the December quarter. UBS has a Neutral rating on review with a target of $6.10.

Target price is $6.10 Current Price is $6.73 Difference: minus $0.63 (current price is over target).
If ALX meets the UBS target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $6.87, suggesting upside of 4.2% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY20:

UBS forecasts a full year FY20 dividend of 24.00 cents.
At the last closing share price the estimated dividend yield is 3.57%.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 14.6, implying annual growth of 484.0%.

Current consensus DPS estimate is 13.6, implying a prospective dividend yield of 2.1%.

Current consensus EPS estimate suggests the PER is 45.1.

Forecast for FY21:

UBS forecasts a full year FY21 dividend of 37.00 cents.
At the last closing share price the estimated dividend yield is 5.50%.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 36.9, implying annual growth of 152.7%.

Current consensus DPS estimate is 31.6, implying a prospective dividend yield of 4.8%.

Current consensus EPS estimate suggests the PER is 17.9.

Market Sentiment: 0.2

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

AMA  AMA GROUP LIMITED

Automobiles & Components

More Research Tools In Stock Analysis - click HERE

Overnight Price: $0.76

UBS rates AMA as Buy (1) -

The divestment of ACAD allows the business to focus on panel repair consolidation. UBS considers the multiple received for the sale was on the low side but strategically the transaction made sense.

The broker believes the second half of FY21 will be key in assessing the operating earnings margin potential of the panel repair business.

Valuation remains appealing and the broker has a Buy rating. Target is raised to $0.86 from $0.80.

Target price is $0.86 Current Price is $0.76 Difference: $0.1
If AMA meets the UBS target it will return approximately 13% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

UBS forecasts a full year FY21 dividend of 0.00 cents and EPS of 2.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 31.67.

Forecast for FY22:

UBS forecasts a full year FY22 dividend of 0.00 cents and EPS of 4.10 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.54.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

AMI  AURELIA METALS LIMITED

Gold & Silver

More Research Tools In Stock Analysis - click HERE

Overnight Price: $0.43

Ord Minnett rates AMI as Buy (1) -

In an effort to allay investor confusion associated with the Dargues transaction, Ord Minnett emphasises the acquisition is good value and there is considerable upside compared to previous conservative assessments of the asset.

The broker reiterates a Buy rating and raises the target to $0.85 from $0.70.

Target price is $0.85 Current Price is $0.43 Difference: $0.42
If AMI meets the Ord Minnett target it will return approximately 98% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 1.00 cents and EPS of 7.00 cents.
At the last closing share price the estimated dividend yield is 2.33%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 6.14.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 2.40 cents and EPS of 10.20 cents.
At the last closing share price the estimated dividend yield is 5.58%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 4.22.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

AX1  ACCENT GROUP LIMITED

Apparel & Footwear

More Research Tools In Stock Analysis - click HERE

Overnight Price: $1.90

Citi rates AX1 as Upgrade to Buy from Neutral (1) -

The update from the AGM has signalled roll-out prospects are better than Citi had anticipated. The business is expected to be a beneficiary of more people going out and about.

Moreover, the broker highlights there is limited exposure to markets with significant disruption from the pandemic and a material growth opportunity in high-margin vertical accessories.

Rating is upgraded to Buy from Neutral and the target raised to $2.09 from $1.60.

Target price is $2.09 Current Price is $1.90 Difference: $0.19
If AX1 meets the Citi target it will return approximately 10% (excluding dividends, fees and charges).

Current consensus price target is $1.98, suggesting upside of 0.2% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Citi forecasts a full year FY21 dividend of 7.50 cents and EPS of 11.60 cents.
At the last closing share price the estimated dividend yield is 3.95%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.38.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.5, implying annual growth of 11.5%.

Current consensus DPS estimate is 9.3, implying a prospective dividend yield of 4.7%.

Current consensus EPS estimate suggests the PER is 17.2.

Forecast for FY22:

Citi forecasts a full year FY22 dividend of 6.80 cents and EPS of 10.90 cents.
At the last closing share price the estimated dividend yield is 3.58%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.43.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.3, implying annual growth of -1.7%.

Current consensus DPS estimate is 9.2, implying a prospective dividend yield of 4.6%.

Current consensus EPS estimate suggests the PER is 17.5.

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Morgan Stanley rates AX1 as Overweight (1) -

Morgan Stanley sees upside for earnings in the wake of a positive trading update by Accent Group. It's considered this will likely come from continued strong sales growth and an expanded store roll-out. 

Sales growth (excluding Auckland and Victoria) was up 15.7% for the first 20 weeks of FY21.

Management is on track to open around 80 stores versus the last target of around 40.

Overweight rating. Target is $2.00. Industry view: In-line.

Target price is $2.00 Current Price is $1.90 Difference: $0.1
If AX1 meets the Morgan Stanley target it will return approximately 5% (excluding dividends, fees and charges).

Current consensus price target is $1.98, suggesting upside of 0.2% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 9.40 cents and EPS of 11.00 cents.
At the last closing share price the estimated dividend yield is 4.95%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.27.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.5, implying annual growth of 11.5%.

Current consensus DPS estimate is 9.3, implying a prospective dividend yield of 4.7%.

Current consensus EPS estimate suggests the PER is 17.2.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 dividend of 9.90 cents and EPS of 10.00 cents.
At the last closing share price the estimated dividend yield is 5.21%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.3, implying annual growth of -1.7%.

Current consensus DPS estimate is 9.2, implying a prospective dividend yield of 4.6%.

Current consensus EPS estimate suggests the PER is 17.5.

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Morgans rates AX1 as Hold (3) -

Morgans upgrades forecasts for Accent Group by around 5% on a higher projected store rollout by management.

Sales growth (excluding Victoria) was up 15.7% for the first 20 weeks of FY21.

The broker believes attractive rental deals, along with a good performance from recently-opened stores have likely contributed to the extra store rollout.

The Hold rating is unchanged and the target increased to $1.86 from $1.67.

Target price is $1.86 Current Price is $1.90 Difference: minus $0.04 (current price is over target).
If AX1 meets the Morgans target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $1.98, suggesting upside of 0.2% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgans forecasts a full year FY21 dividend of 11.00 cents and EPS of 12.00 cents.
At the last closing share price the estimated dividend yield is 5.79%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.83.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.5, implying annual growth of 11.5%.

Current consensus DPS estimate is 9.3, implying a prospective dividend yield of 4.7%.

Current consensus EPS estimate suggests the PER is 17.2.

Forecast for FY22:

Morgans forecasts a full year FY22 dividend of 11.00 cents and EPS of 13.00 cents.
At the last closing share price the estimated dividend yield is 5.79%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.62.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.3, implying annual growth of -1.7%.

Current consensus DPS estimate is 9.2, implying a prospective dividend yield of 4.6%.

Current consensus EPS estimate suggests the PER is 17.5.

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

BHP  BHP GROUP

Bulks

More Research Tools In Stock Analysis - click HERE

Overnight Price: $36.14

Morgan Stanley rates BHP as Overweight (1) -

BHP Group held a commercial round-table which addressed a wide range of topics from near-term demand trends to long-term expectations for the company's core commodities. These included iron ore, coal, and oil products.

Morgan Stanley notes Chinese demand is in a plateau phase. This is considered likely to continue through the middle of the current decade and be followed by a decline. Iron ore demand should under-perform steel production growth given the rising role of scrap in the mix.  

Also, the oil market is still in a recovery mode with an anticipated return to 2019 demand levels. This will likely be followed by very modest demand growth, with a plateau to be reached some time between 2025 and 2035.

Overweight rating is retained with a target price of $40.4. Industry view: Attractive.

Target price is $40.40 Current Price is $36.14 Difference: $4.26
If BHP meets the Morgan Stanley target it will return approximately 12% (excluding dividends, fees and charges).

Current consensus price target is $40.72, suggesting upside of 9.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 204.68 cents and EPS of 288.01 cents.
At the last closing share price the estimated dividend yield is 5.66%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.55.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 318.1, implying annual growth of N/A.

Current consensus DPS estimate is 211.3, implying a prospective dividend yield of 5.7%.

Current consensus EPS estimate suggests the PER is 11.7.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 dividend of 152.05 cents and EPS of 241.23 cents.
At the last closing share price the estimated dividend yield is 4.21%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.98.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 298.3, implying annual growth of -6.2%.

Current consensus DPS estimate is 203.2, implying a prospective dividend yield of 5.5%.

Current consensus EPS estimate suggests the PER is 12.5.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.9

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CAJ  CAPITOL HEALTH LIMITED

Healthcare services

More Research Tools In Stock Analysis - click HERE

Overnight Price: $0.28

Ord Minnett rates CAJ as Accumulate (2) -

Ord Minnett assesses the diagnostic imaging industry has defensive qualities that are appealing for the longer term but the nature of the pandemic means volumes were not immune to declines, of up to -50% in some regions.

Still, the rebound has been swift and consolidation continues. Capitol Health continues to be active, with the acquisition of Direct Radiology. Ord Minnett retains an Accumulate rating and raises the target to $0.30 from $0.28.

Target price is $0.30 Current Price is $0.28 Difference: $0.02
If CAJ meets the Ord Minnett target it will return approximately 7% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 1.00 cents and EPS of 0.90 cents.
At the last closing share price the estimated dividend yield is 3.57%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 31.11.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 1.20 cents and EPS of 1.20 cents.
At the last closing share price the estimated dividend yield is 4.29%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 23.33.

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CBA  COMMONWEALTH BANK OF AUSTRALIA

Banks

More Research Tools In Stock Analysis - click HERE

Overnight Price: $80.00

Morgan Stanley rates CBA as Underweight (5) -

APRA has announced that it will reduce Commonwealth Bank's operational risk overlay. This is given the progress on governance, accountability and risk culture frameworks and practices via its Remedial Action Plan.

Half of the May 2018 capital add-on of around $1bn or circa $12.5bn of risk weighted assets (RWA) will be removed.

This adds around 17 basis points to CET1 capital and lifts the proforma ratio to approximately 12.5%, which implies around $9bn of surplus above the "unquestionably strong" benchmark of 10.5%.

Morgan Stanley expects investors to increasingly focus on the potential for a large buyback with the FY21 or first half FY22 result.

The Underweight rating and target price of $68.50 are unchanged.  Industry view: In-line.

Target price is $68.50 Current Price is $80.00 Difference: minus $11.5 (current price is over target).
If CBA meets the Morgan Stanley target it will return approximately minus 14% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $69.86, suggesting downside of -12.4% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 315.00 cents and EPS of 426.00 cents.
At the last closing share price the estimated dividend yield is 3.94%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.78.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 410.1, implying annual growth of -0.7%.

Current consensus DPS estimate is 266.3, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 19.5.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 dividend of 345.00 cents and EPS of 466.00 cents.
At the last closing share price the estimated dividend yield is 4.31%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.17.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 442.2, implying annual growth of 7.8%.

Current consensus DPS estimate is 326.6, implying a prospective dividend yield of 4.1%.

Current consensus EPS estimate suggests the PER is 18.0.

Market Sentiment: -0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Ord Minnett rates CBA as Hold (3) -

The Australian Prudential Regulation Authority will reduce the $1bn capital add-on applied to Commonwealth Bank by -$500m. This is in response to the bank's progress in addressing concerns over governance and accountability.

Ord Minnett assesses this provides options for capital management. It results in a further increase in the CET1 ratio of 17 basis points, lifting the pro forma ratio to 12.5%.

The broker suspects Commonwealth Bank will be the first major bank to announce capital management post the pandemic. Hold maintained. Target rises to $74.70 from $65.80.

This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.

Target price is $74.70 Current Price is $80.00 Difference: minus $5.3 (current price is over target).
If CBA meets the Ord Minnett target it will return approximately minus 7% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $69.86, suggesting downside of -12.4% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 270.00 cents and EPS of 375.00 cents.
At the last closing share price the estimated dividend yield is 3.38%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.33.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 410.1, implying annual growth of -0.7%.

Current consensus DPS estimate is 266.3, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 19.5.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 320.00 cents and EPS of 426.00 cents.
At the last closing share price the estimated dividend yield is 4.00%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.78.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 442.2, implying annual growth of 7.8%.

Current consensus DPS estimate is 326.6, implying a prospective dividend yield of 4.1%.

Current consensus EPS estimate suggests the PER is 18.0.

Market Sentiment: -0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CCX  CITY CHIC COLLECTIVE LTD

Apparel & Footwear

More Research Tools In Stock Analysis - click HERE

Overnight Price: $2.70

Citi rates CCX as Upgrade to Buy from Neutral (1) -

In its update, City Chic has noted 18.7% comparable growth in sales, excluding the Victorian stores which were closed. Citi expects Australian online sales were likely up more than 50%.

Citi forecasts a -150 basis points decline in gross margin for the City Chic brand and envisages the company will also invest in marketing Avenue.

The company plans a new website in Australia, targeting a lower price point and more conservative fashion style. This will leverage the Avenue range.

Rating is upgraded to Buy from Neutral, as the broker detects improving momentum, and the target is steady at $3.20.

Target price is $3.20 Current Price is $2.70 Difference: $0.5
If CCX meets the Citi target it will return approximately 19% (excluding dividends, fees and charges).

Current consensus price target is $3.68, suggesting upside of 30.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Citi forecasts a full year FY21 dividend of 6.00 cents and EPS of 9.30 cents.
At the last closing share price the estimated dividend yield is 2.22%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 29.03.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 8.9, implying annual growth of 85.4%.

Current consensus DPS estimate is 2.0, implying a prospective dividend yield of 0.7%.

Current consensus EPS estimate suggests the PER is 31.7.

Forecast for FY22:

Citi forecasts a full year FY22 dividend of 8.00 cents and EPS of 12.40 cents.
At the last closing share price the estimated dividend yield is 2.96%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.77.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.3, implying annual growth of 27.0%.

Current consensus DPS estimate is 5.3, implying a prospective dividend yield of 1.9%.

Current consensus EPS estimate suggests the PER is 25.0.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Macquarie rates CCX as Outperform (1) -

City Chic Collective's AGM revealed solid first half sales growth to date of 7.9%, or 18.7% ex-Victoria store closures. Strong momentum in A&NZ online has continued, the broker notes, and Avenue in the US has traded well during election disruption.

The company continues to survey potential M&A opportunities and the broker retains Outperform and a $4.30 target.

Target price is $4.30 Current Price is $2.70 Difference: $1.6
If CCX meets the Macquarie target it will return approximately 59% (excluding dividends, fees and charges).

Current consensus price target is $3.68, suggesting upside of 30.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Macquarie forecasts a full year FY21 dividend of 0.00 cents and EPS of 8.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 32.14.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 8.9, implying annual growth of 85.4%.

Current consensus DPS estimate is 2.0, implying a prospective dividend yield of 0.7%.

Current consensus EPS estimate suggests the PER is 31.7.

Forecast for FY22:

Macquarie forecasts a full year FY22 dividend of 7.80 cents and EPS of 10.40 cents.
At the last closing share price the estimated dividend yield is 2.89%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 25.96.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.3, implying annual growth of 27.0%.

Current consensus DPS estimate is 5.3, implying a prospective dividend yield of 1.9%.

Current consensus EPS estimate suggests the PER is 25.0.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Morgan Stanley rates CCX as Overweight (1) -

Morgan Stanley notes a positive trading update for City Chic Collective, ahead of the broker's expectations.

Comparable sales growth for the first 20 weeks of FY21 were up 18.7% (excluding Victoria).

Gross margins were still down but improving, explains the analyst.

The  Overweight rating is unchanged. Target is $3.55. Industry view is In-line.

Target price is $3.55 Current Price is $2.70 Difference: $0.85
If CCX meets the Morgan Stanley target it will return approximately 31% (excluding dividends, fees and charges).

Current consensus price target is $3.68, suggesting upside of 30.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 0.00 cents and EPS of 9.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 30.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 8.9, implying annual growth of 85.4%.

Current consensus DPS estimate is 2.0, implying a prospective dividend yield of 0.7%.

Current consensus EPS estimate suggests the PER is 31.7.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 dividend of 0.00 cents and EPS of 11.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 24.55.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.3, implying annual growth of 27.0%.

Current consensus DPS estimate is 5.3, implying a prospective dividend yield of 1.9%.

Current consensus EPS estimate suggests the PER is 25.0.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CGF  CHALLENGER LIMITED

Wealth Management & Investments

More Research Tools In Stock Analysis - click HERE

Overnight Price: $5.27

Credit Suisse rates CGF as Outperform (1) -

Credit Suisse increases its valuation for the life business to reflect the potential growth opportunity in the annuity market. The broker reiterates an Outperform rating and raises the target to $6.00 from $4.90.

The broker notes encouraging signs of book growth, a recovery in margins in the second half and a free option on regulatory support amid a strong capital position.

Target price is $6.00 Current Price is $5.27 Difference: $0.73
If CGF meets the Credit Suisse target it will return approximately 14% (excluding dividends, fees and charges).

Current consensus price target is $4.67, suggesting downside of -13.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Credit Suisse forecasts a full year FY21 dividend of 20.00 cents and EPS of 38.00 cents.
At the last closing share price the estimated dividend yield is 3.80%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.87.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 38.6, implying annual growth of N/A.

Current consensus DPS estimate is 19.5, implying a prospective dividend yield of 3.6%.

Current consensus EPS estimate suggests the PER is 14.0.

Forecast for FY22:

Credit Suisse forecasts a full year FY22 dividend of 23.00 cents and EPS of 43.00 cents.
At the last closing share price the estimated dividend yield is 4.36%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.26.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 42.3, implying annual growth of 9.6%.

Current consensus DPS estimate is 24.6, implying a prospective dividend yield of 4.6%.

Current consensus EPS estimate suggests the PER is 12.7.

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

CSL  CSL LIMITED

Pharmaceuticals & Biotech/Lifesciences

More Research Tools In Stock Analysis - click HERE

Overnight Price: $313.53

Morgan Stanley rates CSL as Equal-weight (3) -

The gene therapy company UniQure announced positive data from its Phase III HOPE-B gene therapy trial. This is a gene therapy for the treatment of patients with haemophilia B for which CSL has obtained exclusive global rights to develop and commercialise.

Morgan Stanley calculates upside for CSL by assuming a successful launch and 10% market share by FY25. The broker estimates this could generate US$270m in revenue by FY25 (pre-royalty) and lift EPS by around 4% in FY25.

The Equal-weight rating and $294 price target are unchanged. Industry view: In-line.

Target price is $294.00 Current Price is $313.53 Difference: minus $19.53 (current price is over target).
If CSL meets the Morgan Stanley target it will return approximately minus 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $316.67, suggesting downside of -0.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 EPS of 720.76 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 43.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 679.7, implying annual growth of N/A.

Current consensus DPS estimate is 300.5, implying a prospective dividend yield of 0.9%.

Current consensus EPS estimate suggests the PER is 46.7.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 EPS of 723.68 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 43.32.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 751.0, implying annual growth of 10.5%.

Current consensus DPS estimate is 339.4, implying a prospective dividend yield of 1.1%.

Current consensus EPS estimate suggests the PER is 42.3.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 0.4

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

DHG  DOMAIN HOLDINGS AUSTRALIA LIMITED

Real Estate

More Research Tools In Stock Analysis - click HERE

Overnight Price: $4.41

Morgan Stanley rates DHG as Overweight (1) -

Morgan Stanley remains bullish on the Australian real estate advertising market, due to positive cyclical and structural factors. Accordingly, the broker lifts the EPS forecast for FY22 and FY23 by 17% and 20%, respectively.

While REA Group ((REA)) has been the broker's high-conviction pick, Domain Holdings is suggested to investors wanting maximum, concentrated, high-beta exposure to the Sydney and Melbourne real estate cycle.

The analyst calculates the company offers around twice the EPS leverage to the Australian real estate recovery versus REA Group.

Note: The analyst warns it depends on your appetite for risk and high leverage can cut both ways.

The Overweight rating is unchanged. The target price is increased to $4.90 from $3.40. Industry view is Attractive. 

Target price is $4.90 Current Price is $4.41 Difference: $0.49
If DHG meets the Morgan Stanley target it will return approximately 11% (excluding dividends, fees and charges).

Current consensus price target is $4.44, suggesting upside of 0.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 EPS of 8.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 55.13.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 6.0, implying annual growth of N/A.

Current consensus DPS estimate is 3.4, implying a prospective dividend yield of 0.8%.

Current consensus EPS estimate suggests the PER is 73.5.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 EPS of 12.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 36.75.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 10.3, implying annual growth of 71.7%.

Current consensus DPS estimate is 7.3, implying a prospective dividend yield of 1.7%.

Current consensus EPS estimate suggests the PER is 42.8.

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

GUD  G.U.D. HOLDINGS LIMITED

Household & Personal Products

More Research Tools In Stock Analysis - click HERE

Overnight Price: $11.85

UBS rates GUD as Neutral (3) -

GUD Holdings will acquire AMA Group's ((AMA)) automotive components and accessories division (ACAD) for $70m, to be funded by an institutional placement and share purchase plan.

UBS considers the business is a strong strategic fit within the GUD portfolio and will provide diversification benefits.

The broker updates operating assumptions, incorporating the acquisition and incremental trading update and forecasts $40m in revenue in the second half and a 17% incremental margin. Neutral rating and $12.50 target retained.

Target price is $12.50 Current Price is $11.85 Difference: $0.65
If GUD meets the UBS target it will return approximately 5% (excluding dividends, fees and charges).

Current consensus price target is $12.95, suggesting upside of 5.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

UBS forecasts a full year FY21 dividend of 47.00 cents and EPS of 68.00 cents.
At the last closing share price the estimated dividend yield is 3.97%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.43.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 66.6, implying annual growth of 32.1%.

Current consensus DPS estimate is 44.4, implying a prospective dividend yield of 3.6%.

Current consensus EPS estimate suggests the PER is 18.4.

Forecast for FY22:

UBS forecasts a full year FY22 dividend of 59.00 cents and EPS of 70.00 cents.
At the last closing share price the estimated dividend yield is 4.98%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.93.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 70.6, implying annual growth of 6.0%.

Current consensus DPS estimate is 54.2, implying a prospective dividend yield of 4.4%.

Current consensus EPS estimate suggests the PER is 17.4.

Market Sentiment: 0.5

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

IAG  INSURANCE AUSTRALIA GROUP LIMITED

Insurance

More Research Tools In Stock Analysis - click HERE

Overnight Price: $5.46

Citi rates IAG as Downgrade to Neutral from Buy (3) -

Citi assesses the company is now conservatively provisioned after its capital raising. The perception that Insurance Australia is a quality play in the sector is somewhat dented, in the broker's view.

Estimates for earnings per share are reduced for FY21 by -102% to allow for new business interruption provisioning and the equity raising. Citi downgrades to Neutral from Buy and lowers the target to $5.70 from $6.25.

Target price is $5.70 Current Price is $5.46 Difference: $0.24
If IAG meets the Citi target it will return approximately 4% (excluding dividends, fees and charges).

Current consensus price target is $5.72, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Citi forecasts a full year FY21 dividend of 22.00 cents and EPS of minus 0.70 cents.
At the last closing share price the estimated dividend yield is 4.03%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 780.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 16.6, implying annual growth of -12.9%.

Current consensus DPS estimate is 20.1, implying a prospective dividend yield of 3.9%.

Current consensus EPS estimate suggests the PER is 31.0.

Forecast for FY22:

Citi forecasts a full year FY22 dividend of 24.00 cents and EPS of 29.70 cents.
At the last closing share price the estimated dividend yield is 4.40%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.38.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 32.5, implying annual growth of 95.8%.

Current consensus DPS estimate is 26.0, implying a prospective dividend yield of 5.1%.

Current consensus EPS estimate suggests the PER is 15.8.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Macquarie rates IAG as Outperform (1) -

Insurance Australia Group has shifted $856m into a Business Interruption claims provision and announced a $750m capital raise to fund it. Ahead of the test case that has left insurance companies liable, the stock was trading at a -20% discount to long term averages.

Investors had feared such an outcome, the broker notes, but the capital raise is actually less than -20% and Macquarie suggests the unwinding of this discount will outweigh the dilution of the raising. The dividend is nevertheless in question.

Target falls to $5.30 from $5.50, Outperform retained.

Target price is $5.30 Current Price is $5.46 Difference: minus $0.16 (current price is over target).
If IAG meets the Macquarie target it will return approximately minus 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $5.72, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Macquarie forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 4.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 116.17.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 16.6, implying annual growth of -12.9%.

Current consensus DPS estimate is 20.1, implying a prospective dividend yield of 3.9%.

Current consensus EPS estimate suggests the PER is 31.0.

Forecast for FY22:

Macquarie forecasts a full year FY22 dividend of 28.00 cents and EPS of 36.00 cents.
At the last closing share price the estimated dividend yield is 5.13%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.17.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 32.5, implying annual growth of 95.8%.

Current consensus DPS estimate is 26.0, implying a prospective dividend yield of 5.1%.

Current consensus EPS estimate suggests the PER is 15.8.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Morgan Stanley rates IAG as Overweight (1) -

Insurance Australia Group is taking a total post-tax, post quota share (QS) provision of -$865m. Morgan Stanley estimates that the pre-tax of 30%, pre-quota share reinsurance protection of 32.5%, provision is -$1.83bn.

The broker believes investors will be surprised at the size of the provision, given the risk was well known. When combined with a softer first quarter underlying margin, the analyst considers a de-rating risk is possible.

Morgan Stanley advises the provision may prove to be conservative, given it also allows for prevention of access, but this will not be clear for some time.

Overweight. Target is $6.50. Industry view: In-line.

Target price is $6.50 Current Price is $5.46 Difference: $1.04
If IAG meets the Morgan Stanley target it will return approximately 19% (excluding dividends, fees and charges).

Current consensus price target is $5.72, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 25.00 cents and EPS of 31.00 cents.
At the last closing share price the estimated dividend yield is 4.58%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 16.6, implying annual growth of -12.9%.

Current consensus DPS estimate is 20.1, implying a prospective dividend yield of 3.9%.

Current consensus EPS estimate suggests the PER is 31.0.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 dividend of 28.00 cents and EPS of 31.00 cents.
At the last closing share price the estimated dividend yield is 5.13%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 32.5, implying annual growth of 95.8%.

Current consensus DPS estimate is 26.0, implying a prospective dividend yield of 5.1%.

Current consensus EPS estimate suggests the PER is 15.8.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Ord Minnett rates IAG as Hold (3) -

The company intends to raise up to $750m in new capital for significant increases to business interruption provisions.

Ord Minnett believes this has likely removed business interruption as an issue and shifted the balance towards conservatism and possible capital releases in the future.

The broker maintains a Hold rating and raises the target to $5.10 from $5.08.

This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.

Target price is $5.10 Current Price is $5.46 Difference: minus $0.36 (current price is over target).
If IAG meets the Ord Minnett target it will return approximately minus 7% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $5.72, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 24.00 cents and EPS of minus 5.00 cents.
At the last closing share price the estimated dividend yield is 4.40%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 109.20.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 16.6, implying annual growth of -12.9%.

Current consensus DPS estimate is 20.1, implying a prospective dividend yield of 3.9%.

Current consensus EPS estimate suggests the PER is 31.0.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 24.00 cents and EPS of 28.00 cents.
At the last closing share price the estimated dividend yield is 4.40%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 32.5, implying annual growth of 95.8%.

Current consensus DPS estimate is 26.0, implying a prospective dividend yield of 5.1%.

Current consensus EPS estimate suggests the PER is 15.8.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

IDX  INTEGRAL DIAGNOSTICS LIMITED

Medical Equipment & Devices

More Research Tools In Stock Analysis - click HERE

Overnight Price: $4.29

Ord Minnett rates IDX as Buy (1) -

Ord Minnett assesses the diagnostic imaging industry has defensive qualities that are appealing for the longer term but the nature of the pandemic means volumes were not immune to declines, up to -50% in some regions.

Still, the rebound has been swift and consolidation continues. The broker expects Integral Diagnostics will play at the top end of the market.

Buy rating retained. Target rises to $4.73 from $4.63.

Target price is $4.73 Current Price is $4.29 Difference: $0.44
If IDX meets the Ord Minnett target it will return approximately 10% (excluding dividends, fees and charges).

Current consensus price target is $4.78, suggesting upside of 9.9% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 11.60 cents and EPS of 19.40 cents.
At the last closing share price the estimated dividend yield is 2.70%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 22.11.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 18.9, implying annual growth of 52.1%.

Current consensus DPS estimate is 11.1, implying a prospective dividend yield of 2.6%.

Current consensus EPS estimate suggests the PER is 23.0.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 12.70 cents and EPS of 21.40 cents.
At the last closing share price the estimated dividend yield is 2.96%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.05.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 20.8, implying annual growth of 10.1%.

Current consensus DPS estimate is 13.4, implying a prospective dividend yield of 3.1%.

Current consensus EPS estimate suggests the PER is 20.9.

Market Sentiment: 0.8

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

JHC  JAPARA HEALTHCARE LIMITED

Aged Care & Seniors

More Research Tools In Stock Analysis - click HERE

Overnight Price: $0.79

Morgans rates JHC as Hold (3) -

Recent AGM commentary pointing to difficult conditions in the last quarter, leads Morgans to lower FY21 forecasts on lower occupancy estimates.

After recent takeover activity in the sector, the broker notes two changes to substantial shareholders. Former founder and CEO Andrew Sudholz has increased ownership to 8.1% (was 6.0%) and Aurrum Holdings has become a substantial holder at 6.3%.

Morgans removes a -15% valuation discount and places a 15% premium to reflect potential corporate activity and increases the target price to $0.74 from $0.52.

The Hold rating is unchanged.

Target price is $0.74 Current Price is $0.79 Difference: minus $0.05 (current price is over target).
If JHC meets the Morgans target it will return approximately minus 6% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $0.63, suggesting downside of -24.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgans forecasts a full year FY21 dividend of 2.00 cents and EPS of minus 2.20 cents.
At the last closing share price the estimated dividend yield is 2.53%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 35.91.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -1.4, implying annual growth of N/A.

Current consensus DPS estimate is 0.7, implying a prospective dividend yield of 0.8%.

Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY22:

Morgans forecasts a full year FY22 dividend of 2.00 cents and EPS of 2.00 cents.
At the last closing share price the estimated dividend yield is 2.53%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 39.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 3.1, implying annual growth of N/A.

Current consensus DPS estimate is 1.4, implying a prospective dividend yield of 1.7%.

Current consensus EPS estimate suggests the PER is 27.1.

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

KGN  KOGAN.COM LTD

Retailing

More Research Tools In Stock Analysis - click HERE

Overnight Price: $17.50

Credit Suisse rates KGN as Neutral (3) -

Credit Suisse notes Kogan.com has been well-positioned in the context of household goods expenditure recently. The broker also suggests the medium-term growth story is intact because of the strong private-label offering and a growing product range.

The one issue is the extent to which above-trend growth reverses from the fourth quarter of FY21 and weakens sentiment for the stock. As a result, Credit Suisse retains a Neutral rating and reduces the target to $19.49 from $21.33.

Target price is $19.49 Current Price is $17.50 Difference: $1.99
If KGN meets the Credit Suisse target it will return approximately 11% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

Credit Suisse forecasts a full year FY21 dividend of 39.76 cents and EPS of 53.01 cents.
At the last closing share price the estimated dividend yield is 2.27%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 33.01.

Forecast for FY22:

Credit Suisse forecasts a full year FY22 dividend of 35.89 cents and EPS of 47.85 cents.
At the last closing share price the estimated dividend yield is 2.05%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 36.57.

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


UBS rates KGN as Neutral (3) -

The trading update was solid but below UBS estimates. The broker assesses the business is robust for the longer term, with around 983,000 customers acquired during the pandemic.

Caution prevails because of margin normalisation as the lift in gross margin in the second half is not considered sustainable.

UBS is also cautious about valuation, believing the share price implies 19% online penetration in FY25 compared with 11% today. As bricks & mortar recovers partially and competition in online intensifies, customer acquisition costs are also expected to rise.

Neutral retained. Target is reduced to $18 from $22.

Target price is $18.00 Current Price is $17.50 Difference: $0.5
If KGN meets the UBS target it will return approximately 3% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

UBS forecasts a full year FY21 dividend of 38.00 cents and EPS of 50.00 cents.
At the last closing share price the estimated dividend yield is 2.17%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 35.00.

Forecast for FY22:

UBS forecasts a full year FY22 dividend of 39.00 cents and EPS of 52.00 cents.
At the last closing share price the estimated dividend yield is 2.23%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 33.65.

Market Sentiment: 0.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

LLC  LENDLEASE GROUP

Infra & Property Developers

More Research Tools In Stock Analysis - click HERE

Overnight Price: $14.49

Ord Minnett rates LLC as Hold (3) -

Commentary from the AGM was cautious, Ord Minnett observes. Lendlease has flagged a skew to the second half because of the timing of realised profits from development. No explicit guidance was provided.

The planned sale of 25% of the retirement portfolio is in progress, which will reduce the company's interest to 50%. Ord Minnett suggests the company has stayed on message and retains a Hold rating. Target is $13.20.

This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.

Target price is $13.20 Current Price is $14.49 Difference: minus $1.29 (current price is over target).
If LLC meets the Ord Minnett target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $13.89, suggesting downside of -3.2% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 40.00 cents and EPS of 69.00 cents.
At the last closing share price the estimated dividend yield is 2.76%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 71.1, implying annual growth of N/A.

Current consensus DPS estimate is 34.0, implying a prospective dividend yield of 2.4%.

Current consensus EPS estimate suggests the PER is 20.2.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 44.00 cents and EPS of 86.00 cents.
At the last closing share price the estimated dividend yield is 3.04%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.85.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 95.4, implying annual growth of 34.2%.

Current consensus DPS estimate is 46.3, implying a prospective dividend yield of 3.2%.

Current consensus EPS estimate suggests the PER is 15.0.

Market Sentiment: 0.7

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

LYC  LYNAS CORPORATION LIMITED

Rare Earth Minerals

More Research Tools In Stock Analysis - click HERE

Overnight Price: $3.38

Ord Minnett rates LYC as Buy (1) -

Ord Minnett suggests the fact Lynas Corp may not have been selected by the US Department of Defence for the Light RE tender is immaterial.

The broker continues to believe the stock can re-rate because of commodity price strength and several potential geopolitical catalysts.

The broker lifts earnings estimates by 7% and retains a Buy rating with the target increased to $4.20 from $4.05.

Target price is $4.20 Current Price is $3.38 Difference: $0.82
If LYC meets the Ord Minnett target it will return approximately 24% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 0.00 cents and EPS of 10.60 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 31.89.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 0.00 cents and EPS of 46.40 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.28.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

MX1  MICRO-X LIMITED

Medical Equipment & Devices

More Research Tools In Stock Analysis - click HERE

Overnight Price: $0.34

Morgans rates MX1 as Add (1) -

Morgans notes Micro-X has outlined four platforms for growth, underpinned by the company’s x-ray technology. They are mobile x-ray, back scatter imager, airport self-service checkpoint and CT brain scanner.

Management believes the technology has a five year competitive window to secure a leading position in each of these market segments.

The distribution agreement with Carestream has been amended to be non-exclusive, providing the company with additional channels to sell through.

Morgans makes no changes to forecasts and the increase in price target to $0.50 from $0.32, results from an adjustment to financial modelling assumptions.

The Speculative Buy rating is unchanged.

Target price is $0.50 Current Price is $0.34 Difference: $0.16
If MX1 meets the Morgans target it will return approximately 47% (excluding dividends, fees and charges).

The company's fiscal year ends in June.

Forecast for FY21:

Morgans forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 1.90 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 17.89.

Forecast for FY22:

Morgans forecasts a full year FY22 dividend of 0.00 cents and EPS of 0.70 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 48.57.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

NEC  NINE ENTERTAINMENT CO. HOLDINGS LIMITED

Print, Radio & TV

More Research Tools In Stock Analysis - click HERE

Overnight Price: $2.37

Morgan Stanley rates NEC as Overweight (1) -

The Australian corporate regulator, the ACCC, is developing a mandatory code of conduct to address the bargaining power imbalances between Australian news media businesses and digital platforms, specifically Google and Facebook.

Morgan Stanley highlights a key outcome may be to require the digital platforms to explicitly make some payment for local news content shown on Google Search and Facebook News Feed.

The broker's base case assumes Nine Entertainment receives an incremental $0-30m net revenue stream in perpetuity. The code is expected to be legislated on December 10.

Overweight rating is retained. The target price is increased to $2.70 from $2.40. Industry view: Attractive.

Target price is $2.70 Current Price is $2.37 Difference: $0.33
If NEC meets the Morgan Stanley target it will return approximately 14% (excluding dividends, fees and charges).

Current consensus price target is $2.62, suggesting upside of 9.6% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 6.10 cents and EPS of 10.80 cents.
At the last closing share price the estimated dividend yield is 2.57%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 21.94.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 10.4, implying annual growth of N/A.

Current consensus DPS estimate is 7.4, implying a prospective dividend yield of 3.1%.

Current consensus EPS estimate suggests the PER is 23.0.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 dividend of 6.90 cents and EPS of 11.60 cents.
At the last closing share price the estimated dividend yield is 2.91%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 20.43.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.9, implying annual growth of 14.4%.

Current consensus DPS estimate is 8.7, implying a prospective dividend yield of 3.6%.

Current consensus EPS estimate suggests the PER is 20.1.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

ORI  ORICA LIMITED

Mining Sector Contracting

More Research Tools In Stock Analysis - click HERE

Overnight Price: $16.28

Credit Suisse rates ORI as Neutral (3) -

Credit Suisse notes disappointment with FY21 guidance relative to expectations heading into the results. There were few surprises in aggregate with EBIT of $605m in the middle of guidance.

The broker acknowledges Orica has taken steps to mitigate its exposure to thermal coal, although the company appears to consider the issue mainly as a China-Australian trade concern.

Credit Suisse notes the NSW market is short ammonium nitrate so this is likely to provide strength for Orica's position even in a declining thermal coal market.

The stock appears fairly priced and the broker retains a Neutral rating, reducing the target to $15.91 from $16.41.

Target price is $15.91 Current Price is $16.28 Difference: minus $0.37 (current price is over target).
If ORI meets the Credit Suisse target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $18.32, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY21:

Credit Suisse forecasts a full year FY21 dividend of 50.60 cents and EPS of 82.78 cents.
At the last closing share price the estimated dividend yield is 3.11%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.67.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 87.4, implying annual growth of N/A.

Current consensus DPS estimate is 46.6, implying a prospective dividend yield of 2.8%.

Current consensus EPS estimate suggests the PER is 18.8.

Forecast for FY22:

Credit Suisse forecasts a full year FY22 dividend of 60.44 cents and EPS of 92.30 cents.
At the last closing share price the estimated dividend yield is 3.71%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.64.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 96.5, implying annual growth of 10.4%.

Current consensus DPS estimate is 53.6, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 17.1.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Macquarie rates ORI as Outperform (1) -

Orica's FY20 profit missed the broker on interest charges but earnings were in line with guidance. North America disappointed but other areas performed relatively well, the broker notes, and the Burrup development is tracking to plan.

The broker has cut its target to $19.00 from $19.25 but retains Outperform on leverage to a global economic recovery post-covid and an expectation Orica will be a beneficiary of the shift back to value and cyclicals.

Target price is $19.00 Current Price is $16.28 Difference: $2.72
If ORI meets the Macquarie target it will return approximately 17% (excluding dividends, fees and charges).

Current consensus price target is $18.32, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY21:

Macquarie forecasts a full year FY21 dividend of 40.10 cents and EPS of 83.70 cents.
At the last closing share price the estimated dividend yield is 2.46%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.45.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 87.4, implying annual growth of N/A.

Current consensus DPS estimate is 46.6, implying a prospective dividend yield of 2.8%.

Current consensus EPS estimate suggests the PER is 18.8.

Forecast for FY22:

Macquarie forecasts a full year FY22 dividend of 49.10 cents and EPS of 94.20 cents.
At the last closing share price the estimated dividend yield is 3.02%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.28.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 96.5, implying annual growth of 10.4%.

Current consensus DPS estimate is 53.6, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 17.1.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Morgan Stanley rates ORI as Equal-weight (3) -

Morgan Stanley forecasts anticipated first half FY21 earnings (EBIT) growth. This is now considered unlikely in the wake of reported FY20 results, where operating cash flow disappointed the broker.

In order to meet consensus FY21 expectations, the analyst warns second half FY21 growth would need to exceed 25% versus the previous corresponding period.

Company guidance is for first half FY21 earnings to be lower than the previous corresponding period, but earnings growth at the full-year.

Equal-weight maintained. Target is unchanged at $19. Industry view is Cautious.

Target price is $19.00 Current Price is $16.28 Difference: $2.72
If ORI meets the Morgan Stanley target it will return approximately 17% (excluding dividends, fees and charges).

Current consensus price target is $18.32, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 60.00 cents and EPS of 100.00 cents.
At the last closing share price the estimated dividend yield is 3.69%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.28.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 87.4, implying annual growth of N/A.

Current consensus DPS estimate is 46.6, implying a prospective dividend yield of 2.8%.

Current consensus EPS estimate suggests the PER is 18.8.

Forecast for FY22:

Current consensus EPS estimate is 96.5, implying annual growth of 10.4%.

Current consensus DPS estimate is 53.6, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 17.1.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Morgans rates ORI as Upgrade to Add from Hold (1) -

The FY20 result was in-line with guidance, with earnings particularly weak in the second half, notes Morgans.

Headwinds in emerging economies are flagged to persist into the first half FY21. Guidance for a strong second half onwards has the broker upgrading FY22 and FY23 forecasts.

With 16% upside to a target price of $18.95 (from $15.55), the broker upgrades to Add from Hold.

Target price is $18.95 Current Price is $16.28 Difference: $2.67
If ORI meets the Morgans target it will return approximately 16% (excluding dividends, fees and charges).

Current consensus price target is $18.32, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY21:

Morgans forecasts a full year FY21 dividend of 42.00 cents and EPS of 85.00 cents.
At the last closing share price the estimated dividend yield is 2.58%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.15.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 87.4, implying annual growth of N/A.

Current consensus DPS estimate is 46.6, implying a prospective dividend yield of 2.8%.

Current consensus EPS estimate suggests the PER is 18.8.

Forecast for FY22:

Morgans forecasts a full year FY22 dividend of 51.00 cents and EPS of 101.00 cents.
At the last closing share price the estimated dividend yield is 3.13%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.12.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 96.5, implying annual growth of 10.4%.

Current consensus DPS estimate is 53.6, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 17.1.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Ord Minnett rates ORI as Hold (3) -

FY20 underlying earnings were in line with Ord Minnett's forecasts. The main surprise was the weaker cash conversion because of receivables, which management expects will normalise before the end of the first half.

Management has outlined a path to growth, underpinned by more normal mine activity, incremental earnings from Burrup and the Exsa acquisition.

Ord Minnett factors the benefits into forecasts although remains conscious of the lacklustre performance over recent years. Hold maintained. Target is reduced to $16.50 from $17.00.

This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.

Target price is $16.50 Current Price is $16.28 Difference: $0.22
If ORI meets the Ord Minnett target it will return approximately 1% (excluding dividends, fees and charges).

Current consensus price target is $18.32, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 EPS of 83.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 19.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 87.4, implying annual growth of N/A.

Current consensus DPS estimate is 46.6, implying a prospective dividend yield of 2.8%.

Current consensus EPS estimate suggests the PER is 18.8.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 EPS of 97.00 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.78.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 96.5, implying annual growth of 10.4%.

Current consensus DPS estimate is 53.6, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 17.1.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


UBS rates ORI as Buy (1) -

FYY20 earnings (EBIT) declined -9% and in line with guidance. Depressed global thermal coal prices drove a -13% drop in revenue from that market.

Orica expects organic ammonium nitrate volume growth of 1% in FY21. UBS is pleased Burrup is now operating at 85% and set to deliver the benefit of a full year of earnings.

The broker expects pricing pressure to be a headwind to Australian volumes, as 35% of contracts are due for re-negotiating.

Buy rating retained on valuation grounds and UBS forecasts earnings growth of 5-10% in FY21-22. Target is lowered to $19.40 from $20.25.

Target price is $19.40 Current Price is $16.28 Difference: $3.12
If ORI meets the UBS target it will return approximately 19% (excluding dividends, fees and charges).

Current consensus price target is $18.32, suggesting upside of 11.3% (ex-dividends)

The company's fiscal year ends in September.

Forecast for FY21:

UBS forecasts a full year FY21 dividend of 43.00 cents and EPS of 86.00 cents.
At the last closing share price the estimated dividend yield is 2.64%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 18.93.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 87.4, implying annual growth of N/A.

Current consensus DPS estimate is 46.6, implying a prospective dividend yield of 2.8%.

Current consensus EPS estimate suggests the PER is 18.8.

Forecast for FY22:

UBS forecasts a full year FY22 dividend of 54.00 cents and EPS of 98.00 cents.
At the last closing share price the estimated dividend yield is 3.32%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 96.5, implying annual growth of 10.4%.

Current consensus DPS estimate is 53.6, implying a prospective dividend yield of 3.3%.

Current consensus EPS estimate suggests the PER is 17.1.

Market Sentiment: 0.6

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

OSH  OIL SEARCH LIMITED

NatGas

More Research Tools In Stock Analysis - click HERE

Overnight Price: $3.54

Morgans rates OSH as Downgrade to Hold from Add (3) -

With the Oil Search share price having risen 47% this month, Morgans downgrades the rating to Hold from Add.

The broker warns of potential future funding constraints, which highlights the importance of being able to sell down the Alaskan interests to 36% from 51%.

At the same time the recent investor day illustrated to the analyst how much value the company has added to its Alaskan assets, while also raising concerns about PNG growth.

The target price of $3.65 is unchanged.

Target price is $3.65 Current Price is $3.54 Difference: $0.11
If OSH meets the Morgans target it will return approximately 3% (excluding dividends, fees and charges).

Current consensus price target is $3.61, suggesting downside of -2.5% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY20:

Morgans forecasts a full year FY20 dividend of 0.00 cents and EPS of 5.12 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 69.18.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.5, implying annual growth of N/A.

Current consensus DPS estimate is 0.2, implying a prospective dividend yield of 0.1%.

Current consensus EPS estimate suggests the PER is 148.0.

Forecast for FY21:

Morgans forecasts a full year FY21 dividend of 2.63 cents and EPS of 10.97 cents.
At the last closing share price the estimated dividend yield is 0.74%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 32.28.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 10.8, implying annual growth of 332.0%.

Current consensus DPS estimate is 3.3, implying a prospective dividend yield of 0.9%.

Current consensus EPS estimate suggests the PER is 34.3.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: -0.1

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

REA  REA GROUP LIMITED

Real Estate

More Research Tools In Stock Analysis - click HERE

Overnight Price: $140.51

Morgan Stanley rates REA as Overweight (1) -

Morgan Stanley has done a comparative analysis between Rea Group and Domain Holdings Australia ((DHG)). The broker sees both as out-performers versus the broader market and rates both as Overweight.

Overall, Morgan Stanley remains bullish on the Australian real estate advertising market, due to positive cyclical and structural factors. 

While REA Group has been the broker's high-conviction pick, Domain Holdings is suggested to investors wanting maximum, concentrated, high-beta exposure to the Sydney and Melbourne real estate cycle

Domain Holdings is more leveraged because REA Group is much larger and more diversified (international operations) and Domain Holdings also has higher debt to amplify any EPS impact.

The analyst calculates Domain Holdings offers around twice the EPS leverage to the Australian real estate recovery versus REA Group.

Note: The analyst warns it depends on your appetite for risk and high leverage can cut both ways.

Overweight rating. Target is $150. Industry view: Attractive.

Target price is $150.00 Current Price is $140.51 Difference: $9.49
If REA meets the Morgan Stanley target it will return approximately 7% (excluding dividends, fees and charges).

Current consensus price target is $123.05, suggesting downside of -12.7% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgan Stanley forecasts a full year FY21 dividend of 125.50 cents and EPS of 231.00 cents.
At the last closing share price the estimated dividend yield is 0.89%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 60.83.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 237.0, implying annual growth of 177.8%.

Current consensus DPS estimate is 123.0, implying a prospective dividend yield of 0.9%.

Current consensus EPS estimate suggests the PER is 59.5.

Forecast for FY22:

Morgan Stanley forecasts a full year FY22 dividend of 155.80 cents and EPS of 301.00 cents.
At the last closing share price the estimated dividend yield is 1.11%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 46.68.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 308.1, implying annual growth of 30.0%.

Current consensus DPS estimate is 172.6, implying a prospective dividend yield of 1.2%.

Current consensus EPS estimate suggests the PER is 45.7.

Market Sentiment: 0.2

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

SKO  SERKO LIMITED

Software & Services

More Research Tools In Stock Analysis - click HERE

Overnight Price: $5.50

Macquarie rates SKO as Outperform (1) -

Serko's first half "result" brought unchanged cash-burn guidance of -NZ$2-4m per month on travel guidance of 40-70% pre-covid levels. The broker has looked further into the Bookings.com JV and is now more comfortable with the opportunity.

The broker estimates a possible $3/share and 50% of valuation. Near term catalysts include Melbourne coming out of lockdown, while medium term it depends on a vaccine re-opening Europe. Outperform retained, target rises to NZ$5.91 from NZ$5.51.

Current Price is $5.50. Target price not assessed.

Current consensus price target is $6.55, suggesting upside of 24.3% (ex-dividends)

The company's fiscal year ends in March.

Forecast for FY21:

Macquarie forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 18.30 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 30.05.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -20.2, implying annual growth of N/A.

Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.

Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY22:

Macquarie forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 14.72 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 37.37.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


Ord Minnett rates SKO as Buy (1) -

First half results were slightly better than Ord Minnett expected. The broker was not surprised that the revenue from the traditional online booking business declined materially.

While this revenue stream will remain a core part of the business, successful execution of the Booking.com deal is considered key to future share price performance. Buy rating retained. Target rises to $6.55 from $6.42.

Target price is $6.55 Current Price is $5.50 Difference: $1.05
If SKO meets the Ord Minnett target it will return approximately 19% (excluding dividends, fees and charges).

Current consensus price target is $6.55, suggesting upside of 24.3% (ex-dividends)

The company's fiscal year ends in March.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 0.00 cents and EPS of minus 25.28 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 21.76.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -20.2, implying annual growth of N/A.

Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.

Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY22:

Ord Minnett forecasts a full year FY22 dividend of 0.00 cents and EPS of minus 16.13 cents.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is minus 34.10.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.

Market Sentiment: 1.0

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

SYD  SYDNEY AIRPORT HOLDINGS LIMITED

Infrastructure & Utilities

More Research Tools In Stock Analysis - click HERE

Overnight Price: $6.81

Ord Minnett rates SYD as Lighten (4) -

Sydney Airport has indicated total passenger numbers declined -94% in October, with domestic down -93% and international down -97%.

Ord Minnett assumes domestic traffic recovers to be down -50% by the end of 2020 and international to be down -85%.

While the numbers may appear a little optimistic, the broker believes there is pent-up demand. Lighten rating and $6 target retained.

Target price is $6.00 Current Price is $6.81 Difference: minus $0.81 (current price is over target).
If SYD meets the Ord Minnett target it will return approximately minus 12% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $6.01, suggesting downside of -13.1% (ex-dividends)

The company's fiscal year ends in December.

Forecast for FY20:

Ord Minnett forecasts a full year FY20 dividend of 7.00 cents and EPS of 3.00 cents.
At the last closing share price the estimated dividend yield is 1.03%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 227.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -7.5, implying annual growth of N/A.

Current consensus DPS estimate is 1.0, implying a prospective dividend yield of 0.1%.

Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY21:

Ord Minnett forecasts a full year FY21 dividend of 24.00 cents and EPS of 12.00 cents.
At the last closing share price the estimated dividend yield is 3.52%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 56.75.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 2.0, implying annual growth of N/A.

Current consensus DPS estimate is 12.9, implying a prospective dividend yield of 1.9%.

Current consensus EPS estimate suggests the PER is 346.0.

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

VRT  VIRTUS HEALTH LIMITED

Healthcare services

More Research Tools In Stock Analysis - click HERE

Overnight Price: $5.51

Morgans rates VRT as Downgrade to Hold from Add (3) -

Virtus Health has noted a swift recovery across all geographies in the first quarter, which has resulted in revenue rising 19% on the previous corresponding period.

Morgans expects this level of growth to continue until December and then believes lockdowns overseas may result in some moderation.

The broker makes no changes to forecasts, while also considering future earnings upgrades are likely given positive comments by management.

The Add rating is downgraded to Hold from Add, due to a strong recent share price, and the target is increased to $5.31 from $4.34.

Target price is $5.31 Current Price is $5.51 Difference: minus $0.2 (current price is over target).
If VRT meets the Morgans target it will return approximately minus 4% (excluding dividends, fees and charges - negative figures indicate an expected loss).

Current consensus price target is $4.84, suggesting downside of -11.1% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

Morgans forecasts a full year FY21 dividend of 14.00 cents and EPS of 35.00 cents.
At the last closing share price the estimated dividend yield is 2.54%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 15.74.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 34.9, implying annual growth of 5815.3%.

Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 3.5%.

Current consensus EPS estimate suggests the PER is 15.6.

Forecast for FY22:

Morgans forecasts a full year FY22 dividend of 21.00 cents and EPS of 37.00 cents.
At the last closing share price the estimated dividend yield is 3.81%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.89.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 34.4, implying annual growth of -1.4%.

Current consensus DPS estimate is 21.5, implying a prospective dividend yield of 4.0%.

Current consensus EPS estimate suggests the PER is 15.8.

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources


UBS rates VRT as Buy (1) -

Virtus Health provided a strong trading update, flagging 19% revenue growth in the first quarter. Pre-tax profit rose 86% to $19m.

The pandemic-related restrictions impacted on the company's low-cost clinics while its full-service business grew ahead of the market.

UBS finds market growth remains elevated and believes management will continue to execute on efficiencies and de-leveraging initiatives.

Buy rating retained. Target rises to $5.70 from $4.10.

Target price is $5.70 Current Price is $5.51 Difference: $0.19
If VRT meets the UBS target it will return approximately 3% (excluding dividends, fees and charges).

Current consensus price target is $4.84, suggesting downside of -11.1% (ex-dividends)

The company's fiscal year ends in June.

Forecast for FY21:

UBS forecasts a full year FY21 dividend of 27.00 cents and EPS of 45.00 cents.
At the last closing share price the estimated dividend yield is 4.90%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 12.24.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 34.9, implying annual growth of 5815.3%.

Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 3.5%.

Current consensus EPS estimate suggests the PER is 15.6.

Forecast for FY22:

UBS forecasts a full year FY22 dividend of 25.00 cents and EPS of 38.00 cents.
At the last closing share price the estimated dividend yield is 4.54%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 14.50.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 34.4, implying annual growth of -1.4%.

Current consensus DPS estimate is 21.5, implying a prospective dividend yield of 4.0%.

Current consensus EPS estimate suggests the PER is 15.8.

Market Sentiment: 0.3

All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources

Today's Price Target Changes
Company Last Price Broker New Target Prev Target Change
ALX Atlas Arteria $6.59 Macquarie 6.68 6.73 -0.74%
UBS 6.10 6.50 -6.15%
AMA Ama Group $0.75 UBS 0.86 0.80 7.50%
AMI Aurelia Metals $0.43 Ord Minnett 0.85 0.70 21.43%
ANZ ANZ Banking Group $22.26 Ord Minnett 23.40 20.30 15.27%
AX1 Accent Group $1.98 Citi 2.09 1.60 30.62%
Morgans 1.86 1.67 11.38%
BHP BHP $37.16 Morgan Stanley 40.40 41.00 -1.46%
CAJ Capitol Health $0.28 Ord Minnett 0.30 0.28 7.14%
CBA Commbank $79.79 Ord Minnett 74.70 65.80 13.53%
CCX City Chic $2.82 Morgan Stanley 3.55 3.85 -7.79%
CGF Challenger $5.39 Credit Suisse 6.00 4.90 22.45%
DHG Domain Holdings $4.41 Morgan Stanley 4.90 3.00 63.33%
IAG Insurance Australia $5.14 Citi 5.70 6.25 -8.80%
Macquarie 5.30 5.50 -3.64%
Ord Minnett 5.10 5.08 0.39%
UBS 5.80 6.00 -3.33%
IDX Integral Diagnostics $4.35 Ord Minnett 4.73 4.63 2.16%
JHC Japara Healthcare $0.84 Morgans 0.74 0.52 41.22%
KGN Kogan.Com $17.28 Credit Suisse 19.49 21.33 -8.63%
UBS 18.00 22.00 -18.18%
LLC Lendlease $14.35 Ord Minnett 13.20 13.25 -0.38%
LYC Lynas Corp $3.59 Ord Minnett 4.20 4.05 3.70%
MX1 Micro-X $0.34 Morgans 0.50 0.32 56.25%
NAB National Australia Bank $22.76 Ord Minnett 24.20 20.80 16.35%
NAN Nanosonics $6.48 Ord Minnett 5.05 5.00 1.00%
NEC Nine Entertainment $2.39 Morgan Stanley 2.70 2.40 12.50%
ORI Orica $16.46 Credit Suisse 15.91 16.41 -3.05%
Macquarie 19.00 19.25 -1.30%
Morgans 18.95 15.55 21.86%
Ord Minnett 16.50 17.00 -2.94%
UBS 19.40 20.75 -6.51%
SKO Serko $5.27 Ord Minnett 6.55 6.42 2.02%
VRT Virtus Health $5.44 Morgans 5.31 4.54 16.96%
UBS 5.70 4.10 39.02%
WBC Westpac Banking $19.95 Ord Minnett 20.20 18.10 11.60%
Summaries
3PL 3P Learning Overweight - Morgan Stanley Overnight Price $1.38
ALX Atlas Arteria Downgrade to Neutral from Outperform - Macquarie Overnight Price $6.73
Neutral - UBS Overnight Price $6.73
AMA Ama Group Buy - UBS Overnight Price $0.76
AMI Aurelia Metals Buy - Ord Minnett Overnight Price $0.43
AX1 Accent Group Upgrade to Buy from Neutral - Citi Overnight Price $1.90
Overweight - Morgan Stanley Overnight Price $1.90
Hold - Morgans Overnight Price $1.90
BHP BHP Overweight - Morgan Stanley Overnight Price $36.14
CAJ Capitol Health Accumulate - Ord Minnett Overnight Price $0.28
CBA Commbank Underweight - Morgan Stanley Overnight Price $80.00
Hold - Ord Minnett Overnight Price $80.00
CCX City Chic Upgrade to Buy from Neutral - Citi Overnight Price $2.70
Outperform - Macquarie Overnight Price $2.70
Overweight - Morgan Stanley Overnight Price $2.70
CGF Challenger Outperform - Credit Suisse Overnight Price $5.27
CSL CSL Equal-weight - Morgan Stanley Overnight Price $313.53
DHG Domain Holdings Overweight - Morgan Stanley Overnight Price $4.41
GUD GUD Holdings Neutral - UBS Overnight Price $11.85
IAG Insurance Australia Downgrade to Neutral from Buy - Citi Overnight Price $5.46
Outperform - Macquarie Overnight Price $5.46
Overweight - Morgan Stanley Overnight Price $5.46
Hold - Ord Minnett Overnight Price $5.46
IDX Integral Diagnostics Buy - Ord Minnett Overnight Price $4.29
JHC Japara Healthcare Hold - Morgans Overnight Price $0.79
KGN Kogan.Com Neutral - Credit Suisse Overnight Price $17.50
Neutral - UBS Overnight Price $17.50
LLC Lendlease Hold - Ord Minnett Overnight Price $14.49
LYC Lynas Corp Buy - Ord Minnett Overnight Price $3.38
MX1 Micro-X Add - Morgans Overnight Price $0.34
NEC Nine Entertainment Overweight - Morgan Stanley Overnight Price $2.37
ORI Orica Neutral - Credit Suisse Overnight Price $16.28
Outperform - Macquarie Overnight Price $16.28
Equal-weight - Morgan Stanley Overnight Price $16.28
Upgrade to Add from Hold - Morgans Overnight Price $16.28
Hold - Ord Minnett Overnight Price $16.28
Buy - UBS Overnight Price $16.28
OSH Oil Search Downgrade to Hold from Add - Morgans Overnight Price $3.54
REA REA Group Overweight - Morgan Stanley Overnight Price $140.51
SKO Serko Outperform - Macquarie Overnight Price $5.50
Buy - Ord Minnett Overnight Price $5.50
SYD Sydney Airport Lighten - Ord Minnett Overnight Price $6.81
VRT Virtus Health Downgrade to Hold from Add - Morgans Overnight Price $5.51
Buy - UBS Overnight Price $5.51
RATING SUMMARY
Rating No. Of Recommendations
1. Buy

24

2. Accumulate

1

3. Hold

17

4. Reduce

1

5. Sell

1

Monday 23 November 2020

Access Broker Call Report Archives here

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface. This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.